OYMotion傲意科技 感触未来

OYMotion occupies a cross-disciplinary position spanning biometric sensing, rehabilitation devices, prosthetics, robotics, and AI-based signal interpretation. Its differentiation is the combination of hardware and algorithms: the company develops EMG armbands, wireless acquisition systems, myoelectric prosthetic hands, rehabilitation equipment, EEG devices, and dexterous robotic hands rather than focusing on a single component category. That breadth allows the same core capability—decoding physiological or motion signals into control intent—to serve hospitals, rehabilitation centers, researchers, developers, and robotics manufacturers. The ROHAND portfolio adds a second competitive axis through tactile sensing, force control, adaptive grasping, and multi-protocol integration. Relative to generic sensor manufacturers, OYMotion appears more vertically integrated; relative to specialist prosthetics or rehabilitation vendors, it also addresses robotics development and developer tooling. Its $79.7 million recorded funding total and March 2026 Series C place it among better-capitalized private companies in the emerging neuro-AI and bionic robotics segment, while its estimated employee band of 11–50 suggests a compact operating footprint relative to the breadth of its product portfolio.

OYMotion’s trajectory shows a progression from early-stage sensing and gesture-control technology toward a broader bionic systems platform. The company was founded in 2015 and raised a $720,000 Angel round that year, followed by a $1.2 million Series A in 2016. A Venture Round in 2020 has no disclosed amount, while the 2022 Series B recorded approximately $14.5 million. Capital deployment accelerated sharply in 2025, with three additional Series B transactions totaling approximately $41.9 million, followed by a $21.8 million Series C on Mar 25, 2026. The financing sequence is consistent with a company moving from component and developer products into higher-value clinical and robotics applications, although revenue and shipment data are unavailable. Product breadth supports that interpretation: gForce devices provide EMG and motion data, OHand targets assistive prosthetics, rehabilitation products address healthcare workflows, and ROHAND targets dexterous manipulation. The Jun 8, 2026 ICRA showcase of ROH-AP003, incorporating 3D magnetic tactile sensing, marks a notable technical inflection point from signal acquisition toward multimodal robotic perception. Active recruitment channels indicate continued hiring, but no headcount growth rate or role-level expansion is disclosed.